Anika Therapeutics Inc
ANIK
View Detailed Chart
10.460USD
+0.160+1.55%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
150.84MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.55%
5 Days
+13.33%
1 Month
+8.28%
6 Months
+26.79%
Year to Date
+8.84%
1 Year
-41.20%
View Detailed Chart
TradingKey Stock Score of Anika Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Anika Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 9 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 16.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Anika Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Anika Therapeutics Inc Highlights
StrengthsRisks
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 119.91M.
Fairly Valued
The company’s latest PE is -4.61, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.37M shares, decreasing 0.01% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 533.02K shares of this stock.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
16.000
Target Price
+55.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Anika Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Anika Therapeutics Inc Info
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Ticker SymbolANIK
CompanyAnika Therapeutics Inc
CEOBlanchard (Cheryl Renee)
Websitehttps://anika.com/
Related Instruments
+3.02%
+0.09%
+1.60%
+2.48%
+0.40%
-1.14%
-0.05%
-2.35%
-1.76%
+2.65%
+2.64%
+2.03%
+2.01%
+2.38%
+1.70%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68446.920
-1523.210 (-2.18%)
282.580
+22.390 (+8.61%)
2032.060
-19.670 (-0.96%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
